“This achievement demonstrates our team’s ability to innovate for the benefit of clinicians and their patients. The Sentimag® platform is the first and only non-radioactive solution approved in the U.S. that can perform lesion localisation and sentinel node biopsy. The addition of Magtrace to the platform offers clinicians greater options and more flexibility when treating their patients and will help transform the way breast cancer is treated in the U.S.," said Eric Mayes, CEO at Endomag
University Hospitals System Adopts Magseed Marker as Standard of Care for Localization of Impalpable Breast Lesions
Endomag, the surgical guidance company, announced today that University Hospitals (UH), one of the leading healthcare systems in the US, providing high-quality, patient-centred cancer care at locations throughout Northeast Ohio, has expanded the use of its Magseed®...
2/22/18: Endomag, the surgical guidance company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to extend the indication of its Magseed® magnetic marker to include both the marking of soft tissue and long-term implantation.
Ochsner Health System adopts Magseed® as Standard of Care for Localization of Impalpable Breast Lesions
Magseed technology guides surgeons during a breast lumpectomy to simplify treatment and improve patient experience Endomag, the cancer healthcare company, announced today that Ochsner Health System has adopted Magseed® as the standard of care for breast lesion localization,...